MA28490B1 - Formulations galeniques de composes organiques - Google Patents

Formulations galeniques de composes organiques

Info

Publication number: MA28490B1
Authority: MA; Morocco
Prior art keywords: organic compounds; galenic formulations; galenic; formulations; compounds
Prior art date: 2004-03-17

Application number

MA29347A

Other languages

English (en)

Inventor

Hiroki Koike

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-17

Filing date

2006-09-27

Publication date

2007-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28490(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-27 Application filed by Novartis Ag filed Critical Novartis Ag

2007-03-01 Publication of MA28490B1 publication Critical patent/MA28490B1/fr

Links

239000000203 mixture Substances 0.000 title 1
150000002894 organic compounds Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA29347A 2004-03-17 2006-09-27 Formulations galeniques de composes organiques MA28490B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US55387804P	2004-03-17	2004-03-17

Publications (1)

Publication Number	Publication Date
MA28490B1 true MA28490B1 (fr)	2007-03-01

Family

ID=34994415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA29347A MA28490B1 (fr)	2004-03-17	2006-09-27	Formulations galeniques de composes organiques

Country Status (24)

Country	Link
US (3)	US8617595B2 (fr)
EP (2)	EP2283826B1 (fr)
JP (2)	JP2007529456A (fr)
KR (2)	KR101353736B1 (fr)
CN (2)	CN1997354B (fr)
AR (1)	AR048431A1 (fr)
AU (2)	AU2005224010B2 (fr)
BR (1)	BRPI0508833A (fr)
CA (1)	CA2554633C (fr)
EC (1)	ECSP066807A (fr)
ES (1)	ES2747941T3 (fr)
IL (1)	IL177424A0 (fr)
MA (1)	MA28490B1 (fr)
MX (1)	MX347617B (fr)
MY (2)	MY144477A (fr)
NO (1)	NO343217B1 (fr)
NZ (1)	NZ548823A (fr)
PE (3)	PE20142101A1 (fr)
RU (3)	RU2384328C2 (fr)
SG (1)	SG153830A1 (fr)
TN (1)	TNSN06294A1 (fr)
TW (1)	TWI406656B (fr)
WO (1)	WO2005089729A2 (fr)
ZA (1)	ZA200606220B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2340484T3 (es) *	2002-11-05	2010-06-04	Glaxo Group Limited	Agentes antibacterianos.
US20070191487A1 (en) *	2004-03-17	2007-08-16	Rigassi-Dietrich Petra G	Galenic formulations of organic compounds
TW200804241A (en) *	2006-02-24	2008-01-16	Novartis Ag	New salt
GB0605688D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic compounds
CN101415413A (zh) *	2006-04-03	2009-04-22	诺瓦提斯公司	用于治疗高血压的肾素抑制剂
GB0612540D0 (en) *	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
EP1891937A1 (fr) *	2006-08-25	2008-02-27	Novartis AG	Formulations galéniques de l'aliskiren
CA2563690C (fr) *	2006-10-12	2014-10-07	Pharmascience Inc.	Compositions pharmaceutiques comprenant des fractions intra- et extra- granulaires
US8119841B2 (en) *	2006-11-07	2012-02-21	Novartis Ag	Crystalline forms of aliskiren hemifumarate
ATE555082T1 (de) *	2006-11-09	2012-05-15	Novartis Ag	Salz von aliskiren mit orotsäure
WO2008098992A1 (fr) *	2007-02-16	2008-08-21	Novartis Ag	Utilisation de composés organiques
EP1972335A1 (fr) *	2007-03-23	2008-09-24	Krka	Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables
US20090082458A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched aliskiren
WO2009045795A2 (fr) *	2007-09-28	2009-04-09	Novartis Ag	Formulations galéniques de composés organiques
PE20091203A1 (es) *	2007-09-28	2009-09-11	Novartis Ag	Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo
WO2009045796A1 (fr) *	2007-09-28	2009-04-09	Novartis Ag	Combinaison pharmaceutique d'aliskirène et de valsartane
JP2011503185A (ja)	2007-11-13	2011-01-27	テバファーマシューティカルインダストリーズリミティド	ヘミフマル酸アリスキレンの多形形態及びその調製プロセス
EP2062874B1 (fr)	2007-11-20	2014-12-17	KRKA, tovarna zdravil, d.d., Novo mesto	Procédé et intermédiaires pour la préparation d'aliskiren
CN102143939A (zh) *	2008-06-06	2011-08-03	特瓦制药工业有限公司	阿利吉仑游离碱的固体形式
EP2143425A1 (fr) *	2008-07-11	2010-01-13	Ratiopharm GmbH	Tablettes d'aliskiren comprimées directement
US20100093603A1 (en) *	2008-07-17	2010-04-15	Kenneth Baker	Use of organic compounds
JO3239B1 (ar) *	2008-09-22	2018-03-08	Novartis Ag	تركيبات جالينية من مركبات عضوية
US9026212B2 (en)	2008-09-23	2015-05-05	Incube Labs, Llc	Energy harvesting mechanism for medical devices
AR073651A1 (es) *	2008-09-24	2010-11-24	Novartis Ag	Formulaciones galenicas de compuestos organicos
SI2189442T1 (sl)	2008-11-20	2015-03-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Postopek in intermediati za pripravo aliskirena
CN102300558A (zh) *	2009-01-28	2011-12-28	诺瓦提斯公司	有机化合物的盖伦制剂
EP2216020A1 (fr)	2009-02-05	2010-08-11	KRKA, tovarna zdravil, d.d., Novo mesto	Processus de granulation à humidité activée
EA201190091A1 (ru)	2009-02-05	2012-01-30	Крка, Товарна Здравил, Д. Д., Ново Место	Активируемый влагой способ грануляции
EP2340820A1 (fr)	2009-12-16	2011-07-06	KRKA, tovarna zdravil, d.d., Novo mesto	Processus de granulation à humidité activée
CN102348452A (zh)	2009-03-20	2012-02-08	诺瓦提斯公司	缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
MX2011009844A (es) *	2009-03-20	2011-09-29	Novartis Ag	Composicion farmaceutica que comprende alisquireno.
JP2010280601A (ja) *	2009-06-04	2010-12-16	Suntory Holdings Ltd	キシロオリゴ糖高含有錠剤
US20120220663A1 (en)	2009-09-03	2012-08-30	Teva Pharmaceuticals Usa, Inc.	Solid forms of aliskiren hemifumarate and processes for preparation thereof
EP2382967A1 (fr)	2010-04-21	2011-11-02	ratiopharm GmbH	Aliskiren sous forme d'une dispersion solide
EP2382969A1 (fr)	2010-04-30	2011-11-02	Sanovel Ilac Sanayi ve Ticaret A.S.	Formulations d'Aliskiren multi-couches
US20130129791A1 (en) *	2010-05-04	2013-05-23	Mahmut Bilgic	Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
CN105050708A (zh)	2012-11-14	2015-11-11	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
CN103099793B (zh) *	2013-02-06	2015-07-15	中国人民解放军第二军医大学	片剂及其制备方法
CN103536576B (zh) *	2013-10-15	2015-07-01	海南卫康制药(潜山)有限公司	阿利吉仑组合物胶囊
RU2545833C1 (ru) *	2013-12-03	2015-04-10	Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России)	Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения
CA2937365C (fr)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
ES3036307T3 (en) *	2019-12-31	2025-09-17	Jiangsu Yahong Meditech Co Ltd	Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3039922A (en) *	1959-08-17	1962-06-19	Carter Prod Inc	Method of administering tablets having decongestant and anti-histaminic activity
MY119161A (en)	1994-04-18	2005-04-30	Novartis Ag	Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19820801A1 (de) *	1998-05-09	1999-11-25	Gruenenthal Gmbh	Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
ATE404178T1 (de) *	1999-02-10	2008-08-15	Pfizer Prod Inc	Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6264983B1 (en) *	1999-09-16	2001-07-24	Rhodia, Inc.	Directly compressible, ultra fine acetaminophen compositions and process for producing same
CA2420055C (fr)	2000-08-25	2010-06-01	Takeda Chemical Industries, Ltd.	Agent de reduction du fibrinogene
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7316819B2 (en) *	2001-03-08	2008-01-08	Unigene Laboratories, Inc.	Oral peptide pharmaceutical dosage form and method of production
EP1250921A1 (fr) *	2001-04-21	2002-10-23	BOEHRINGER INGELHEIM INTERNATIONAL GmbH	Comprimé de meloxicam à désintégration rapide
JP2003015880A (ja) *	2001-06-29	2003-01-17	Toshiba Corp	携帯情報端末およびアドインプログラム起動方法
US20040266836A1 (en) *	2001-10-18	2004-12-30	Peter Buhlmayer	Organic compounds
US20030114389A1 (en) *	2001-11-13	2003-06-19	Webb Randy Lee	Combination of organic compounds
BR0310084A (pt) *	2002-05-17	2005-02-15	Novartis Ag	Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
DE60309472T2 (de) *	2002-06-28	2007-06-28	Speedel Pharma Ag	Pharmazeutische formulierung mit einem nicht peptidischen renin-hemmer und surfactant
US20040002520A1 (en) *	2002-07-01	2004-01-01	Soderlund Patrick L.	Composition and method for cessation of Nicotine cravings

2005
- 2005-03-15 AR ARP050100999A patent/AR048431A1/es not_active Application Discontinuation
- 2005-03-15 MY MYPI20051084A patent/MY144477A/en unknown
- 2005-03-15 PE PE2014001265A patent/PE20142101A1/es not_active Application Discontinuation
- 2005-03-15 PE PE2005000288A patent/PE20060075A1/es not_active Application Discontinuation
- 2005-03-15 PE PE2010000272A patent/PE20110121A1/es not_active Application Discontinuation
- 2005-03-15 MY MYPI20090494A patent/MY148773A/en unknown
- 2005-03-16 EP EP10177494.1A patent/EP2283826B1/fr not_active Expired - Lifetime
- 2005-03-16 SG SG200904140-1A patent/SG153830A1/en unknown
- 2005-03-16 CN CN2005800062331A patent/CN1997354B/zh not_active Expired - Fee Related
- 2005-03-16 KR KR1020137005111A patent/KR101353736B1/ko not_active Expired - Fee Related
- 2005-03-16 CN CN2013103391479A patent/CN103462913A/zh active Pending
- 2005-03-16 ES ES10177494T patent/ES2747941T3/es not_active Expired - Lifetime
- 2005-03-16 CA CA2554633A patent/CA2554633C/fr not_active Expired - Fee Related
- 2005-03-16 MX MX2012004612A patent/MX347617B/es unknown
- 2005-03-16 NZ NZ548823A patent/NZ548823A/en not_active IP Right Cessation
- 2005-03-16 KR KR1020067018968A patent/KR101274855B1/ko not_active Expired - Fee Related
- 2005-03-16 TW TW094108055A patent/TWI406656B/zh not_active IP Right Cessation
- 2005-03-16 AU AU2005224010A patent/AU2005224010B2/en not_active Ceased
- 2005-03-16 RU RU2006136090/15A patent/RU2384328C2/ru not_active IP Right Cessation
- 2005-03-16 WO PCT/EP2005/002798 patent/WO2005089729A2/fr not_active Ceased
- 2005-03-16 BR BRPI0508833-0A patent/BRPI0508833A/pt not_active Application Discontinuation
- 2005-03-16 JP JP2007503280A patent/JP2007529456A/ja not_active Withdrawn
- 2005-03-16 US US10/590,398 patent/US8617595B2/en active Active
- 2005-03-16 EP EP05716117A patent/EP1729736A2/fr not_active Ceased
- 2005-04-29 US US11/119,273 patent/US7683054B2/en not_active Expired - Fee Related
- 2005-06-15 US US11/153,728 patent/US8007824B2/en active Active
2006
- 2006-07-27 ZA ZA2006/06220A patent/ZA200606220B/en unknown
- 2006-08-10 IL IL177424A patent/IL177424A0/en not_active IP Right Cessation
- 2006-08-30 EC EC2006006807A patent/ECSP066807A/es unknown
- 2006-09-15 TN TNP2006000294A patent/TNSN06294A1/en unknown
- 2006-09-27 MA MA29347A patent/MA28490B1/fr unknown
- 2006-10-16 NO NO20064670A patent/NO343217B1/no not_active IP Right Cessation
2009
- 2009-05-26 AU AU2009202069A patent/AU2009202069B2/en not_active Ceased
- 2009-10-20 RU RU2009138446/15A patent/RU2438661C2/ru not_active IP Right Cessation
2011
- 2011-08-25 RU RU2011135405/15A patent/RU2480210C1/ru not_active IP Right Cessation
2012
- 2012-06-06 JP JP2012129230A patent/JP5925607B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2007529456A (ja)	2007-10-25
EP2283826B1 (fr)	2019-09-04
SG153830A1 (en)	2009-07-29
CA2554633A1 (fr)	2006-09-29
CA2554633C (fr)	2014-07-08
US8007824B2 (en)	2011-08-30
MY148773A (en)	2013-05-31
RU2438661C2 (ru)	2012-01-10
TW200534843A (en)	2005-11-01
EP2283826A2 (fr)	2011-02-16
JP2012211152A (ja)	2012-11-01
RU2384328C2 (ru)	2010-03-20
EP1729736A2 (fr)	2006-12-13
MX347617B (es)	2017-05-04
WO2005089729A3 (fr)	2006-10-12
BRPI0508833A (pt)	2007-08-14
AU2005224010A1 (en)	2005-09-29
PE20110121A1 (es)	2011-02-28
MY144477A (en)	2011-09-30
CN103462913A (zh)	2013-12-25
TNSN06294A1 (en)	2007-12-03
AU2009202069B2 (en)	2012-02-16
CN1997354A (zh)	2007-07-11
AU2009202069A1 (en)	2009-06-18
KR20130028803A (ko)	2013-03-19
RU2480210C1 (ru)	2013-04-27
EP2283826A3 (fr)	2013-08-07
ECSP066807A (es)	2006-11-16
RU2009138446A (ru)	2011-04-27
KR20070006776A (ko)	2007-01-11
ES2747941T3 (es)	2020-03-12
RU2006136090A (ru)	2008-04-27
KR101274855B1 (ko)	2013-06-13
IL177424A0 (en)	2008-03-20
ZA200606220B (en)	2008-04-30
JP5925607B2 (ja)	2016-05-25
AR048431A1 (es)	2006-04-26
US8617595B2 (en)	2013-12-31
RU2011135405A (ru)	2013-03-10
KR101353736B1 (ko)	2014-01-22
NO343217B1 (no)	2018-12-03
PE20060075A1 (es)	2006-03-20
CN1997354B (zh)	2013-09-11
PE20142101A1 (es)	2014-12-27
WO2005089729A2 (fr)	2005-09-29
US7683054B2 (en)	2010-03-23
US20050272790A1 (en)	2005-12-08
US20060018960A1 (en)	2006-01-26
TWI406656B (zh)	2013-09-01
US20070197655A1 (en)	2007-08-23
NO20064670L (no)	2006-10-16
NZ548823A (en)	2011-02-25
AU2005224010B2 (en)	2009-02-26

Publication	Publication Date	Title
IL177424A0 (en)	2008-03-20	Galenic formulations of organic compounds
CY2022001I1 (el)	2022-03-24	Παραγωγα του uk-2a
BRPI0715621A2 (pt)	2014-05-20	Formulações galênicas de compostos orgânicos
EP1888534A4 (fr)	2010-06-16	Composes organiques
BRPI0817442A2 (pt)	2015-06-16	Formulações galênicas de composto orgânicos
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
ITMI20050191A1 (it)	2005-08-11	Struttura di fet ad alette
MA29033B1 (fr)	2007-11-01	Composes organiques
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP1981547A4 (fr)	2009-05-06	Formulations therapeutiques stables
BRPI0913379A2 (pt)	2015-11-24	formulações farmacêuticas sólidas compreendendo bibw 2992
EP2046361A4 (fr)	2011-06-29	Composition d'amplification d'activité ostéogène
MA28535B1 (fr)	2007-04-03	Utilisation de composes organiques
FR2873585B1 (fr)	2006-11-17	Nouvelles formulations galeniques de principes actifs
EP1799271A4 (fr)	2010-05-05	Administration de polynucléotides
EP2042174A4 (fr)	2012-10-10	Préparation d'adhésif
CR9144A (es)	2007-11-23	Formulaciones de benzoxazoles sustituidos
PT1850664E (pt)	2014-03-26	Formulação de cápsulas
EP1719409A4 (fr)	2010-09-22	Composition insecticide
ZA200705363B (en)	2008-08-27	Pharmaceutical compositions comprising amorphous benzimidazole compounds
NO20043305D0 (no)	2004-08-09	Preparation of lodixanol
IL180031A0 (en)	2007-05-15	Stable pharmaceutical formulations of benzimidazole compounds
HUE031355T2 (hu)	2017-07-28	Vízben nem oldódó aktív szerves vegyületek kompozíciói
BRPI0817586A2 (pt)	2015-03-31	Formulações galênicas de compostos orgânicos